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Background. Iron deficiency and anemia are commonly en-
countered in patients with autoimmune diseases undergoing
immune apheresis. This makes erythropoietin and iron substitu-
tion necessary in most patients. However, intravenous iron ther-
apy may result in an increase of potentially toxic nontransferrin-
bound iron.
Methods. We examined the effect of 50 mg or 100 mg of iron
(III) sucrose on bleomycin-detectable iron (BDI) in immune
apheresis patients. Six patients with autoimmune disorders and
normal kidney function were enrolled. Before and after the
injection of 50 mg or 100 mg of iron (III) sucrose, BDI was
measured in serum samples at five different time points.
Results. There was no BDI traceable before injection of iron
(III) sucrose. BDI was present in serum of all patients after the
administration of 100 mg of iron (III) sucrose in concentrations
up to 0.49 lmol/L. In contrast, only one patient showed BDI
at a concentration of 0.16 lmol/L after the administration of
50 mg of iron (III) sucrose.
Conclusion. We conclude that if parenteral iron is adminis-
tered after apheresis treatment, despite the equal tolerability,
use of 50 mg of iron (III) sucrose is superior to 100 mg of
iron (III) sucrose in avoiding the formation of potentially toxic
nontransferrin-bound iron.
Immune apheresis is an extracorporeal therapy critical
in the management of disorders caused by autoantibod-
ies. An apheresis treatment is a modified plasmapheresis
that conveys a specific adsorption of human immunoglob-
ulin molecules for efficient clearance of circulating au-
toantibodies. Thus far, this method has been successfully
used in humoral kidney graft rejection, systemic lupus
Key words: anemia, bleomycin-detectable iron, immune apheresis, iron
deficiency, iron (III) sucrose.
Received for publication September 29, 2003
and in revised form December 16, 2003, and December 30, 2003
Accepted for publication February 2, 2004
C© 2004 by the International Society of Nephrology
erythematosus, anti-phospholipid antibody syndrome,
multifocal motor neuropathy, paraneoplastic pemphigus,
Goodpasture syndrome, myasthenia gravis, Basedow-
Graves disease, elimination of antibodies against several
factors of the hemostasis system, systemic connective tis-
sue disease, and primary vasculitis [1–8].
Iron deficiency and anemia are commonly encountered
in patients with autoimmune diseases undergoing im-
mune apheresis, even if the kidney function is normal.
Currently, 22 of 24 patients in our apheresis program
present with iron deficiency and/or anemia. To date, the
underlying mechanisms are not completely understood.
Plausible explanations for the anemia include: anemia of
chronic disease [9]; the inhibitory effect of immunosup-
pressive therapy on erythropoiesis [10]; binding of iron
to citrate [11] used for anticoagulation during apheresis;
or frequent blood sampling. Although immune aphere-
sis was invented to selectively remove antibodies, there
is still loss of other plasma proteins with iron-binding ca-
pacity. The magnitude of this loss has been stated contro-
versially in the literature. Albumin losses vary from less
than 10% to 25% [12–14]. A decrease in other plasma
proteins was not detectable, or was 14% per apheresis
treatment [12, 14]. This protein loss may also contribute
to the iron deficiency observed in patients undergoing
immune apheresis treatment.
In order to counteract the iron deficiency leading to
anemia and related morbidity, especially cardiovascular
complications such as left ventricular hypertrophy [15],
routine treatment for patients in the apheresis program at
our department includes erythropoietin and intravenous
iron substitution. But iron therapy, although indicated,
carries potential risks [16]. The first to mention are acute
toxic effects such as back pain, nausea, vomiting, hypoten-
sion, and allergic or anaphylactic reactions. Anaphylaxis
is caused by the dextran component of iron dextran and
practically not seen with current iron preparations, iron
sucrose, or iron gluconate [17, 18]. In addition, there are
studies suggesting a possible relationship between iron
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and infectious [19, 20] or atherosclerotic [21, 22] compli-
cations. This is, however, still a controversy because to
date epidemiologic studies failed to demonstrate such a
correlation [23–25].
It is believed that in vivo iron toxicity appears when
transferrin can no longer scavenge the excess of inor-
ganic iron. This occurs in states of iron overload, such
as hemochromatosis [26], thalassemia [27], or introduc-
tion of large amounts of iron into the circulation, as well
as low transferrin levels [28]. All of these factors can lead
to a nontransferrin-bound labile iron ion fraction. This
labile iron fraction is commonly measured as bleomycin-
detectable iron (BDI), and relies on the degradation of
DNA by bleomycin in the presence of nontransferrin-
bound iron (NTBI) ions. It is conceivable that patients
undergoing immune apheresis are at higher risk to be ex-
posed to higher concentrations of labile iron after iron
substitutions because apheresis causes a state of hypo-
transferrinemia resulting from the protein loss. Although
harmful effects of NTBI have not been examined in epi-
demiologic studies and therefore not proven, there are
many good reasons to protect patients from exposure to
these labile iron ions. Noteworthy are endothelial dys-
function [29], leukocyte dysfunction [30–32], loss of the
ability of patient serum to resist the growth of Staphylo-
coccus epidermidis [28], or formation of reactive oxygen
species [33]. These toxic oxygen radicals lead to de-
polymerization of polysaccharides, breakages in DNA
strands, or lipid peroxidation, with consequential injury
and death of the cell [34].
A common dose of parenteral iron (III) sucrose for
therapy of iron deficiency is 100 mg, but other doses are
used as well [17, 35–37]. BDI was detected after injection
of 100 mg of iron (III) sucrose in healthy individuals [29]
or in patients with renal disease [38]. However, it is un-
known whether administration of lower doses of iron (III)
sucrose has a similar effect in inducing BDI in patients
treated for iron deficiency. In this study we examined the
effect of 50 mg or 100 mg of intravenous iron (III) su-
crose on BDI in patients undergoing immune apheresis
treatment.
METHODS
Hypothesis
We hypothesized that intravenous administration of
iron (III) sucrose at a dose of 100 mg of elemental iron
results in a more pronounced generation of serum BDI
compared with injection of 50 mg of iron (III) sucrose.
Participants
We included immune apheresis patients treated at the
apheresis unit of the Department of Medicine III at the
University of Vienna Medical School. Eligibility criteria
for this study were iron deficiency defined as a serum
ferritin <18 lg/L in men or <30 lg/L in women, or
a transferrin saturation <16%, and normal serum cre-
atinine. The exclusion criteria comprised pregnancy or
lactation, hemochromatosis, and hemolytic anemia.
The study was carried out in accordance with the
European Union Good Clinical Practice (EU-GCP)
guideline, the Austrian Arzneimittelgesetz 1993, and
the Declaration of Helsinki (1964), including current
revisions. The Ethics Committee of the University
of Vienna Medical School approved the study proto-
col. All patients gave written informed consent before
participation.
Study design and interventions
This study was a single-center, controlled trial. Patients
were enrolled to receive 50 mg or 100 mg of iron (III) su-
crose (Venofer®, Vifor International, St. Gallen, Switzer-
land) intravenously at the end of two immune aphere-
sis treatments (each treatment consisted of two immune
apheresis sessions on two days) that were performed ac-
cording to the standard procedure at our hospital as pre-
viously described [39]. Patients received 50 mg of iron
(III) sucrose after the first treatment and 100 mg of iron
(III) sucrose after the second treatment.
Blood was drawn before apheresis session on day 1
(“pre-apheresis”), and after the second session on day 2
before the iron (III) sucrose injection (“zero”), as well as
5 minutes, 30 minutes, and 24 hours after iron (III) sucrose
injection. Subjects were discharged thereafter. We used
washout periods of 2 to 4 weeks between the study days
(on average 23 days). The same protocol was repeated
with the second treatment.
Outcomes
The primary outcome was defined as the maximal in-
crease of serum BDI after injection of iron (III) sucrose.
A less pronounced increase to <33% of BDI after injec-
tion of low versus high dose iron (III) sucrose therapy
was regarded as a clinically relevant effect.
Secondary outcome variables included serum iron lev-
els, serum transferrin levels, transferrin saturation, serum
ferritin levels, and serum albumin concentrations.
Sample size
An increase of nontransferrin bound iron from 0.03
up to 0.29 lmol/L was demonstrated after a single-dose
administration of 100 mg of iron (III) sucrose in 12
hemodialysis patients [28]. Based on the assumption that
a lower iron (III) sucrose dose would result in a 66%
lower level of nontransferrin-bound iron compared with
the higher dose of iron (III) sucrose, six individuals were
necessary at an alpha of 0.05 and a power of 80%.
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Laboratory analyses
Blood chemistry and complete blood counts were de-
termined by standard methods in an International Or-
ganization for Standardization (ISO) 9001:2000 certi-
fied clinical laboratory at the University Hospital of Vi-
enna. For analysis of BDI serum was kept in plastic,
trace element–free tubes at −20◦C. In each blood sam-
ple BDI as well as serum iron (reference range 40 to 150
lg/dL), ferritin (reference range 10 to 250 lg/L), transfer-
rin (reference range 200 to 360 mg/dL), transferrin satu-
ration (reference range 16% to 45%), and albumin (ref-
erence range 35 to 55 g/L) were determined. For serum
iron determination the FerroZine method (Boehringer
Mannheim, Mannheim, Germany) was used. The test
principle is based on the release of Fe3+ from transfer-
rin resulting from guanidiumchloride in an environment
with a pH of 5.0. Ascorbic acid in the buffer provided re-
duces this iron to Fe2+, which builds a chromogenic com-
plex with FerroZine reagent, quantified using Hitachi 747
equipment.
Transferrin saturation was calculated using the follow-
ing equation: transferrin saturation (%) = (iron in serum
(lg/dL)/transferrin in serum (mg/dL) × 71.
BDI was measured as described by Gutteridge et al
with some modifications [40]. Calf thymus DNA (Sigma-
Aldrich, St. Louis, MO, USA) was dissolved in water
to a concentration of 0.1 mol/L at room temperature,
and was then kept at 4◦C overnight. Bleomycin sul-
fate (Lundbeck, Copenhagen, Denmark) was diluted
in water to a final concentration of 1.5 U/mL. A Tris-
HCl buffer solution with a pH of 7.4 was prepared
(Merck, Whitehouse Station, NJ, USA). A stock solu-
tion of ascorbic acid (Merck) in water (0.7 g in 10 mL)
was freshly prepared before each experiment. Atomic
absorption spectroscopy grade iron (III) nitrate in ni-
tric acid (Merck) was prepared and diluted to 0.5, 1.0,
1.5, 2.0, 3.0, 4.0, and 5.0 lmol/L solutions to generate
a standard curve. All reagents, except bleomycin sul-
fate and iron (III) nitrate, were treated overnight with
Chelex resin (Bio-Rad, Hercules, CA, USA) (300 mg per
10 mL solution) to remove any possible iron contami-
nation. The following reagents were pipetted into each
of the standard or sample tubes in the following order:
0.5 mL DNA (1 mg/mL), 0.05 mL bleomycin (1.5 U/mL),
0.1 mL MgCl2 (50 mmol/L; Merck), 0.05 mL Tris
(1 mol/L), 0.1 mL ascorbic acid (0.75 mmol/L), 0.15 mL
water, 0.05 mL standard, or sample.
pH was adjusted to 7.4 to 7.8. All tubes were incubated
at 37◦C for 1 hour and the reaction was terminated with
0.1 mol/L EDTA (Sigma-Aldrich). A half milliliter of HCl
25% and 0.5 mL of thiobarbituric acid (TBA) (1% w/v in
50 mmol/L NaOH; Merck) were added. All tubes were
then kept at 80◦C for 20 minutes, and cooled down with
3 mL of n-buthyl alcohol (Merck). Finally, tubes were
Table 1. Characteristics of enrolled patients (N = 6, mean ± SD)
Age years 42.0 ± 7.8
Apheresis therapy prior to the study months 7.5 ± 5.4
Apheresis sessions prior to the study N 44.5 ± 22.6
Serum creatinine mg/dL 0.78 ± 0.07
Weekly s.c. erythropoietin dose IU 5833 ± 2500
Hemoglobin at the beginning of the study g/dL 10.2 ± 1.6
GFR, glomerular filtration rate; s.c., subcutaneous.
centrifuged for 20 minutes at 2300g, and from each tube
0.1 mL was transferred into a 96-well plate (Costar, Cam-
bridge, MA, USA) in duplicates. The chromogenic reac-
tion was measured with a fluorescent reader (CytoFluor
Fluorescence Measurement System 2300; Millipore, Bil-
lerica, MA, USA) using CytoCalc Software (version 3.0;
PerSeptive Biosystems, Framingham, MA, USA). The fil-
ters were set to 590 ± 35 nm for emission, and 530 ±
25 nm for excitation. The standard curve showed a linear
increase in BDI up to 3 lmol/L and started to come to a
plateau at 5 lmol/L.
Statistical methods
Chi-square tests and comparison of dependent samples
(Student t test) for continuous variables were performed
using Statistica for Windows 5.1 (Stat Soft, Inc., Tulsa,
OK, USA).
Safety
Patients were observed during the entire therapy ses-
sion by specially trained apheresis nurses. A physician
examined each patient at every apheresis session. Side
effects and symptoms were documented on a standard-
ized treatment chart.
RESULTS
Patients
Six female patients were eligible and enrolled to the
study. Baseline demographic and clinical data of all
patients enrolled are shown in Table 1. All had an autoim-
mune disorder (3 endocrine orbitopathies and 3 myasthe-
nia gravis) that was resistant to conventional therapy. One
out of six patients was under immunosuppressive therapy
with azathioprine at the time of the study.
Bleomycin-detectable iron
We found no BDI before apheresis or at the time of in-
jection of iron (III) sucrose (“pre-apheresis” and “zero”
time points). We detected BDI in concentrations up to
0.49 lmol/L in serum samples of all patients (9 of the 18
measurements) after the injection of 100 mg of iron (III)
sucrose (Fig. 1). In contrast, after the injection of 50 mg of
iron (III) sucrose, BDI was found only in one patient (1 of
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Fig. 1. Course of BDI after injection of 100 mg of iron (III) sucrose
in 6 patients [preapheresis (PA), 0 minutes, 5 minutes, 30 minutes, and
24 hours].
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Fig. 2. Course of BDI after injection of 50 mg of iron (III) sucrose in
6 patients [preapheresis (PA), 0 minutes, 5 minutes, 30 minutes, and
24 hours].
the 18 measurements) at a concentration of 0.16 lmol/L
(Fig. 2) (v 2 test: P = 0.003).
Serum iron
Serum iron increased in all patients rapidly in the time
interval from 5 minutes to 30 minutes (Tables 2 and 3).
Although a plateau was reached and a slight decline was
observed around 30 minutes, iron levels remained sig-
nificantly elevated in the interval from 30 minutes to
24 hours. The increase in all time points (5 minutes, 30
minutes, and 24 hours) after injection of iron (III) sucrose
was significant when compared to preapheresis values (50
mg group: P < 0.05, P < 0.01, P < 0.0001, respectively,
and 100 mg group: P < 0.005, P < 0.0001, P < 0.0001, re-
spectively). There was no difference between preaphere-
sis and zero-time point levels. The increase in serum iron
was more prominent after the application of 100 mg of
iron (III) sucrose compared to 50 mg of iron (III) sucrose
at 5 minutes, at 30 minutes, as well as at 24-hour time
points (P < 0.005, P < 0.003, P < 0.05, respectively).
Serum transferrin
Serum transferrin levels decreased immediately after
the apheresis treatment and reached the initial level ap-
proximately 24 hours later (Tables 2 and 3). The compar-
ison of preapheresis values with 0, 5-minute, 30-minute
time points showed a decrease (50 mg group: P < 0.0001,
P < 0.0001, P < 0.005, respectively, and 100 mg group:
P < 0.0005, P < 0.0005, P < 0.001, respectively). We
did not observe a difference between the 50 mg and the
100 mg iron (III) sucrose groups regarding transferrin
levels.
Transferrin saturation
Transferrin saturation increased after the iron injec-
tion in both the 50 mg and the 100 mg group until
30 minutes and then started to decline, but did not reach
the pretreatment values (Tables 2 and 3). The compar-
ison of preapheresis levels with each of the time points
0, 5 minutes, 30 minutes, 24 hours revealed significant in-
creases in each group (50 mg group: P < 0.005, P < 0.0005,
P < 0.0001, P < 0.03, respectively, and 100 mg group: P <
0.03, P < 0.003, P < 0.0005, P < 0.03, respectively). There
was no difference in comparison of 50 mg versus 100 mg
except at the 30-minute time point (43.4 ± 14.0% vs.
64.7 ± 24.2%, P < 0.01).
Serum ferritin
Ferritin levels increased only 24 hours after the injec-
tion of iron in the 50 mg group from a preapheresis level
of 12.2 ± 9.41 lg/L to 53.9 ± 17.0 lg/L (P < 0.03), and
in the 100 mg group from a preapheresis level of 9.17 ±
6.96 lg/L to 103.5 ± 41.8 lg/L (P < 0.001) (Tables 2 and
3). This increase was more pronounced after injection of
100 mg of iron (III) sucrose compared with 50 mg (P <
0.02).
Serum albumin
After apheresis treatment, serum albumin levels de-
creased immediately and reached the initial level approx-
imately 24 hours later (Tables 2 and 3). The comparison
of preapheresis values with 0, 5-minute, 30-minute time
points showed statistically significant decreases (50 mg
group: P < 0.0001, P < 0.0001, P < 0.001, respectively,
and 100 mg group: P < 0.0005, P < 0.0005, P < 0.0005,
respectively). The decrease in serum albumin level was
not different between the 50 mg and the 100 mg iron (III)
sucrose groups.
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Table 2. Time course of iron metabolism parameters before and after the application of 50 mg of iron (III) sucrose (N = 6, mean ± SD)
Preapheresis Zero 5 min 30 min 24 h
Serum iron lg/dL 27.3 ± 15.8 52.5 ± 27.6 133.3 ± 32.9a 129.7 ± 34.1b 110.3 ± 52.8c
Transferrin mg/dL 289.3 ± 44.1 195.3 ± 24.8c 194.7 ± 32.2c 206.2 ± 19.6d 291.3 ± 39.5
Transferrin saturation % 7.4 ± 5.4 20.0 ± 12.4d 50.9 ± 19.5e 45.2 ± 14.4c 27.5 ± 13.0f
Ferritin lg/L 13.0 ± 10.0 8.7 ± 7.6 8.9 ± 8.3 9.6 ± 9.8 55.9 ± 17.6f
Serum albumin g/L 41.6 ± 4.1 34.0 ± 3.4c 34.9 ± 3.3c 36.9 ± 3.6g 45.8 ± 4.6
Preapheresis, 24 hours prior to the immune apheresis session; zero, Immediately after the immune apheresis session and immediately before the iron injection; 5 min,
Five minutes after the iron injection; 30 min, Thirty minutes after the iron injection; 24 h, twenty-four hours after the iron injection.
aP < 0.05, bP < 0.01, cP < 0.0001, dP < 0.005, eP < 0.0005, fP < 0.03, gP < 0.001. All P values are from comparison to preapheresis.
Table 3. Time course of iron metabolism parameters before and after the application of 100 mg of iron (III) sucrose (N = 6, mean ± SD)
Preapheresis Zero 5 min 30 min 24 h
Serum iron lg/dL 40.3 ± 29.4 63.2 ± 44.2 242.2 ± 161.5a 195.2 ± 60.1b 203.7 ± 136.2b
Transferrin mg/dL 285.0 ± 17.4 208.3 ± 15.0c 206.3 ± 17.5c 212.3 ± 19.0d 297.5 ± 38.1
Transferrin saturation % 10.1 ± 7.5 22.0 ± 16.8e 86.3 ± 60.3f 66.8 ± 25.7c 50.8 ± 35.6e
Ferritin lg/L 9.7 ± 7.49 8.1 ± 4.9 8.0 ± 4.9 8.4 ± 4.86 110.6 ± 40.9d
Serum albumin g/L 43.3 ± 5.5 34.2 ± 2.4c 33.6 ± 2.6c 35.2 ± 2.6c 43.6 ± 3.6
Preapheresis, 24 hours prior to the immune apheresis session; zero, Immediately after the immune apheresis session and immediately before the iron injection; 5 min,
Five minutes after the iron injection; 30 min, Thirty minutes after the iron injection; 24 h, twenty-four hours after the iron injection.
aP < 0.05, bP < 0.0001, cP < 0.0005, dP < 0.001, eP < 0.03, fP < 0.003. All P values are from comparison to preapheresis.
Side effects of intravenous iron therapy
Both dosages of iron (III) sucrose (50 and 100 mg) were
injected within 5 minutes because it was reported to be
safe [41]. None of the possible acute side effects of intra-
venous iron (III) sucrose [42] were encountered in any of
the patients during or after the drug administration.
DISCUSSION
We showed that parenteral administration of 100 mg
of iron (III) sucrose resulted in an increase of
nontransferrin-bound iron, measured as bleomycin-
detectable iron, whereas 50 mg of iron (III) sucrose had
no major effect on BDI in immune apheresis patients.
Bleomycin is a glycopeptide that binds to DNA and
causes single- and double-strand breakages. In addi-
tion, degradation of deoxyribose occurs. One of the fi-
nal metabolites of this degradation is malondialdehyde,
which reacts with thiobarbituric acid (TBA) to give a pink
chromogen. Thus, the TBA test can be used to follow
DNA degradation by bleomycin. The DNA degradation
has an absolute requirement for certain transition metal
ions such as iron. Therefore, chromogen development
is proportional to iron concentration. This test is estab-
lished to measure the availability of iron complexes that
can catalyze free radical reactions such as formation of
OH− from H2O2. One of the key issues is that bleomycin
cannot remove iron from its binding proteins (transfer-
rin, ferritin, lactoferrin, hemoglobin, and others) in a pH
range of 7.4 to 7.8. Bleomycin-detectable iron represents
mostly nontransferrin bound, and thus, catalytic iron,
with the potential to form free hydroxyl radicals. These
are involved in depolymerization of polysaccharides and
breakages in DNA strands, which can lead to dysfunc-
tion, injury, and death of the cell [34]. Atherogenic fac-
tors such as cholesterol oxidation products, oxysterols,
or lipid peroxidation were also linked to pro-oxidative
properties of iron [34, 43]. An increased abundance of
the reactive oxygen species was demonstrated after nu-
tritional iron overload in rats [44]. Appearance of BDI
after “oversaturation” of transferrin was shown in var-
ious patient groups, including hematologic patients un-
dergoing high-dose chemotherapy or stem cell transplan-
tation, and some patients with septic shock [45–47]. An
increase of nontransferrin-bound iron was also reported
for hemodialysis patients who received 100 mg of iron
(III) sucrose [38].
Although widely discussed and believed, the long-term
consequences of iron therapy are an ongoing controversy.
Two studies published by Hoen et al [24, 25] failed to
demonstrate a correlation between iron therapy and an
increased risk for infection. However, at the same time
there are numerous in vivo and in vitro data suggesting a
role of iron in infectious complications caused by leuko-
cyte dysfunction or iron’s effect on bacterial growth [28,
30–32, 48]. It was previously suggested that fever pro-
motes resistance to infection by lowering the concentra-
tion of iron in serum [49], but this could be solely caused
by a negative acute-phase response. Similarly, there are
convincing data both showing no correlation between
iron and atherosclerosis [23, 50–53], as well as demon-
strating such a link [54–57]. Possible reasons for these con-
flicting results and potential problems with epidemiologic
studies were reviewed previously [21, 22]. It is known
that in a multifactorial disease like atherosclerosis it is
extremely difficult to demonstrate the importance of a
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single risk factor. In the case of iron’s role in infection or
atherosclerosis, it is even more challenging because of the
different forms of iron. There is not a single epidemiologic
study examining the role of NTBI in that matter, although
the availability of catalytic iron, rather than the overall
iron status, might be the factor causing the risk. Two stud-
ies with small patient numbers that measured NTBI in
serum of patients with iron overload demonstrated oxy-
gen radical stress and endothelial dysfunction [29], as well
as a diminished resistance to bacterial growth [28]. Gaen-
zer et al described endothelial dysfunction leading to an
increased intima-media thickness of the carotid artery in
hemochromatosis patients [55], while de Valk et al [58]
detected NTBI in patients with this disease, supporting
the link between NTBI and endothelial dysfunction.
One reason for the lack of large epidemiologic stud-
ies so far might be the elaborate methods for detection
of NTBI, such as the bleomycin procedure described in
this paper. A new method with the potential to overcome
this problem has been developed [59]. There are already
data from patients with thalassemia demonstrating re-
dox activity of labile iron using this one-step fluorescence
based method [60]. Epidemiologic studies incorporating
NTBI levels in patients undergoing iron therapy with long
follow-up periods would finally provide us with conclu-
sive data about iron’s role in infection, atherosclerosis,
and mortality.
Even though the potential risks stemming from the use
of iron as a therapeutic agent are significant, based on the
long-term consequences of anemia, iron therapy is indis-
pensable. It was shown that hemodialysis patients with
hematocrit levels over 36% had significantly lower hos-
pitalization rates compared with patients with hematocrit
levels between 33% and 36% [61]. Anemia was shown as
one of the two major predictors of left ventricular growth,
which in turn is a predictor of death and heart failure in
patients with renal disease [15]. We counteract iron de-
ficiency and anemia in our apheresis patients with intra-
venous iron instead of oral substitution, although they
are not uremic, and thus, have a normal gastrointestinal
iron absorption capacity because it is the most efficient
way to fill the iron stores. This is convenient in apheresis
patients because of the readily available venous access.
Our results showed that 50 mg and 100 mg of intra-
venous iron (III) sucrose normalized the ferritin levels
after 24 hours of administration. One hundred mg of iron
(III) sucrose was more efficient in increasing serum iron
levels, filling the iron storages, and producing significantly
higher ferritin concentrations than 50 mg of iron (III) su-
crose. In all patients the immune apheresis treatment it-
self caused an immediate decline in serum transferrin and
serum albumin levels, as detected directly after apheresis
session. However, serum iron and BDI did not increase
during apheresis session. When the proteins with iron-
binding properties were at their minimum (between zero
and 5-minute time points), 50 or 100 mg of iron (III)
sucrose was administered. Consequently, transferrin sat-
uration increased rapidly after the slow intravenous in-
jection of iron, and reached the peak levels in the interval
between 5 minutes and 30 minutes after the injection. The
increase in transferrin saturation was significantly higher
after intravenous administration of 100 mg of iron (III)
sucrose compared with 50 mg. In parallel to the increase
of transferrin saturation, BDI appeared after administra-
tion of 100 mg of iron (III) sucrose in all patients at various
time points. In contrast, only one patient presented with
a BDI level at one time point after injection of 50 mg of
iron.
Of interest, no patient experienced adverse side effects,
regardless of the dose of iron sucrose or evidence of the
presence or absence of NTBI. These findings suggest that
at the detected levels, NTBI either lacks clinical signifi-
cance or poses risks that lack symptoms. If the latter is the
case, serum iron and therefore serum transferrin satura-
tion may not be reliable predictors of NTBI early after
intravenous iron administration.
The abrupt rise of serum iron after intravenous iron
sucrose (Tables 2 and 3) should be interpreted with cau-
tion because the presence of intravenous iron agent in
serum may falsely elevate the reported serum iron using
the ferrozine-ascorbate method [62].
Our studies are the first to demonstrate a dose-
response relationship between intravenous iron admin-
istration and BDI in patients. BDI is a measure of NTBI.
NTBI, in turn, is thought to be one manifestation of
the labile iron fraction released from all intravenous
iron agents [63]. Quantitative in vitro studies, reported
in abstract form [Lewis JM et al, J Am Soc Nephrol
14:771A, 2003], suggest that among available intravenous
iron agents BDI release follows the sequence ferric glu-
conate > iron sucrose > iron dextran. Comparative in
vivo studies to our knowledge have not been performed.
Our data document that 50 mg of iron (III) sucrose
given intravenously does not result in detectable levels
of nontransferrin-bound iron in most immune apheresis
patients. In contrast, 100 mg of the same iron preparation
led to the formation of nontransferrin-bound iron in all
patients enrolled in the study. Thus, we suggest avoiding
an exposure to high-dose iron to prevent potential long-
term risks arising from nontransferrin-bound iron.
It is noteworthy that the iron injection is usually per-
formed immediately after the apheresis treatment. Ac-
cording to our data this is not an optimal time point for
application of high dose (≥100 mg) iron therapy because
apheresis causes an artifical state of hypotransferrine-
mia caused by the protein loss. This corresponds to data
from hemodialysis patients with a low transferrin level
[38]. Therefore, it is not excluded that in these patients
the main actor in the generation of BDI is the aphere-
sis therapy and timing of iron injection, rather than the
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iron therapy itself. Although it was not the subject of this
study and therefore not examined, we suggest that if high
doses of iron (III) sucrose are indicated, later time points
(e.g., 24 hours after apheresis treatment) should be cho-
sen because serum transferrin and albumin reach their
preapheresis levels at this time.
CONCLUSION
In apheresis patients with iron deficiency receiving
intravenous iron sucrose, generation of nontransferrin-
bound iron in serum is dose-dependent, transient, and
related to the reduction in iron-binding capacity caused
by apheresis.
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